Kailasam V, Mathews K P
J Am Acad Dermatol. 1987 Apr;16(4):797-804. doi: 10.1016/s0190-9622(87)70104-2.
Astemizole, one of the newer generation of nonsedating antihistamines, was evaluated in a double-blind study of forty-six patients who had chronic idiopathic urticaria with or without angioedema; most had severe disease. Nineteen of twenty-three patients who were on placebo discontinued treatment because of lack of response compared to only five of twenty-three astemizole-treated patients (p less than 0.0001). Fourteen of twenty-two astemizole-treated patients and two of twenty-two placebo-treated patients considered the results to be good or excellent (p less than 0.0001). Blinded assessment by the investigators yielded similar results (p less than 0.0001). Therapeutic response was the same in patients with and without angioedema in addition to urticaria and in those requiring corticosteroids. Duration of urticaria also did not influence the results. Increased appetite and weight gain were the main side effects reported more frequently in the astemizole-treated than in the placebo-treated group, and no significant toxicity was noted. Follow-up after terminating the drug study indicated a high frequency of remissions during the subsequent year.
阿司咪唑是新一代非镇静性抗组胺药之一，在一项针对46例患有慢性特发性荨麻疹伴或不伴血管性水肿的患者的双盲研究中进行了评估；大多数患者病情严重。接受安慰剂治疗的23例患者中有19例因无反应而停止治疗，相比之下，接受阿司咪唑治疗的23例患者中只有5例（p小于0.0001）。接受阿司咪唑治疗的22例患者中有14例、接受安慰剂治疗的22例患者中有2例认为结果良好或极佳（p小于0.0001）。研究人员进行的盲法评估得出了类似结果（p小于0.0001）。除了荨麻疹患者外，伴有和不伴有血管性水肿的患者以及需要使用皮质类固醇的患者的治疗反应相同。荨麻疹的持续时间也未影响结果。与安慰剂治疗组相比，接受阿司咪唑治疗的组中更频繁报告的主要副作用是食欲增加和体重增加，且未发现明显毒性。在药物研究结束后的随访表明，随后一年中缓解的频率很高。
